Nitric Oxide Consumption as a Predictor of Vasospasm in Subarachnoid Hemorrhage
Massachusetts General Hospital · with Fondazione Policlinico Universitario Agostino Gemelli IRCCS · NCT07614906
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Observational
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- March 3, 2024
- Record last updated
- May 29, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this observational study is to understand if angiographic cerebral vasospasm (CV) can be predicted by levels of nitric oxide (NO) consumption in patients with aneurysmal subarachnoid hemorrhage (SAH). To reach this goal, the investigators will compare NO consumption levels in SAH and non-SAH patients. NO consumption levels will be analyzed from samples of participants' cerebral spinal fluid (CSF).
Conditions: Aneurysmal Subarachnoid Hemorrhage; Cerebral Vasospasm
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Adult
- patient with SAH and with an external ventricular drainage (EVD) placed within 24 hours after the onset of the hemorrhage
Exclusion Criteria
- pregnancy
- pre-existing neurological comorbidities
- coagulation disorders
- anemia
- absence of a good cranial window to perform Transcranial Doppler (TDC)
- presence of >50% stenosis of carotid arteries confirmed by doppler ultrasound
- Technical problems on EVD that prevent CSF withdrawals
For the control group, we will invite to participate patients without neurological comorbidities undergoing spinal anesthesia in the operating room or with a spinal drain for major vascular surgery.
Recruiting US locations
Massachusetts General Hospital
Boston, MA 02114
Site contact: Lorenzo Berra, MD · 617-726-3030 · lberra@mgh.harvard.edu
Study contacts (from the official record)
- Lorenzo Berra, MD · 617-726-3030 · lberra@mgh.harvard.edu
Similar studies in Massachusetts
All healthy volunteers studies in Massachusetts →- RecruitingHealthy volunteersPhase 1/Phase 2
A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
Novartis Pharmaceuticals
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Evaluate the Safety, Pharmacokinetic, and Pharmacodynamic Effects of MY006 in Healthy Volunteers and Patients With Peanut Allergy
Mabylon AG
- Location
- Boston, MA + 7 other US sites
- Eligibility basics
- Ages 12–55
- RecruitingHealthy volunteersPhase 1
Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HTX-001
Haya Therapeutics, Inc.
- Location
- Boston, MA + 1 other US site
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Boston, MA + 49 other US sites
- Eligibility basics
- Ages 60+